Abstract:Background The concept of Mixed Connective Tissue Disease (MCTD) was first proposed by Sharp and his colleagues in 1972.1 MCTD has overlapping features between at least two autoimmune diseases, such as SLE, SSc, PM/DM and RA. Regulatory T cells (Treg cells) play a critical role in the maintenance of immune tolerance and the regulation of immune responses. Treg cell dysfunction contributes to the initiation of pathogenesis and the maintenance of high disease activity in RA and SLE.2 Recently, some studies have indicated that the proportion of Treg cells was different from healthy controls in SSc patients.3 Therefore, MCTD may be associated with Treg cells. Objectives To explore the status of CD4+T cells in peripheral blood of patients with MCTD; to explore the effect of low dose interleukin -2 (IL-2) treatment on the balance of Treg cells and Th17 cells in patients with MCTD, and to observe the short-term curative effect. Methods CD4+T cells in the peripheral blood of 58 MCTD patients and 33 healthy controls were analyzed by flow cytometry. All of 58 cases were treated with standard therapy, including corticosteroids, NSAIDs, immunosuppressants, or combination therapy. Among them, 26 cases of MCTD without using immunosuppressant (CYC, MTX, LEF, MMF), were as untreated group, another 32 cases were as treated group. Then we compared the difference of CD4+T cells between two groups. In 58 patients with MCTD, a total of 27 patients were treated with low-dose IL-2 (50WIU) on the basis of standard treatment for 5 days. The difference of CD4+T cells before and after treatment with IL-2 was compared. Results The absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD was significantly lower than those in healthy controls. There was no significant difference in the absolute count of CD4+CD25+FOXP3+Treg cells in the peripheral blood between the treated group and the untreated group. The absolute count of CD4+CD25+FOXP3+Treg cells was significantly higher than those before treatment with IL-2. Conclusions The absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD were significantly reduced, which may be the mechanism of immune imbalance in MCTD patients. The decrease of the absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD was not associated with the use of immunosuppressive agents. Low dose and short-term IL-2 treatment may increase the absolute count of CD4+CD25+FOXP3+Treg cells in the peripheral blood in patients with MCTD, so as to restore the immune balance in patients with MCTD. References Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specifi c antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148–159. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol, 2009, 16(4):274–279. Cordiali-Fei P, Mussi A, D9Agosto G, et al. Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol, 2013, 2013:390563. Acknowledgements Thanks to my supervisor, my colleagues and superiors. Disclosure of Interest None declared

Treatment with Levamisole and Colchicine Can Result in A Significant Reduction of Il-6, Il-8 or Tnf-Alpha Level in Patients with Mucocutaneous Type of Behcet'S Disease

IDDF2024-ABS-0420 Successful Treatment with Upadacitinib in Four Patients of Intestinal Behcet’s Disease with Ineffective Anti-Tnf Therapy

Plasma and Whole-Blood Chemokine Levels in Patients with Behcet's Disease

A prospective clinical study of metformin for Behcet's disease of mucocutaneous type

Efficacy and Safety of Metformin for Behcet's Disease and Its Effect on Treg/Th17 Balance:A Single-Blinded, Before-after Study

AB0612 Efficacy of Low Dose and Short-Term IL-2 Treatment to Expand Endogenous Regulatory T Cells in Patients with Mixed Connective Tissue Disease

The effect of colchicine treatment on complete blood cell count-based parameters in patients with Behçet's disease

Mucosal healing in intestinal Behcet's disease: A systematic review and meta-analysis

Refractory Behçet's Disease Treated with Low-Dose Interleukin-2: A Case Report.

Mycophenolate mofetil combined with low dose prednisone in the treatment for adults with minimal change nephrotic syndrome and concomitant HBsAg positive

P591 Treatment of microscopic colitis: retrospective analysis of consecutive single centre patients

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Effects Of Mycophenolate Mofetil Combined With Corticosteroids For Induction Therapy Of Microscopic Polyangiitis

Efficacy and Safety of Low-Dose Interleukin 2 for Behçet’s Syndrome: a Phase 2 Randomized Double-Blind Placebo-Controlled Clinical Trial

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

Serum GAS6, sAXL, IL-10, NO, and BCL-2 levels are decreased in patients with Behçet’s disease

Clinical Study on Therapeutic Effect of Acupuncture on Behcet's Disease.

Profile of immunological biomarkers in Behcet's syndrome: a large-scale single-center real-world study

P1068 Limited long-term efficacy of corticosteroids in microscopic colitis emphasizing the need for advanced therapies

P021 Higher TNFα and IL-6 mucosal levels in ulcerative colitis patients with more severe endoscopic activity

Clinical features analysis of 36 cases of intestinal Behcet's disease